This newly discovered activity of the p53 gene offers a potential avenue of attack on breast cancer stem cells thought to play a central role in progression and spread of the disease, according to scientists at The University of Texas MD … to a mesenchymal cell type is important because that change plays an essential role in cancer metastasis,” said senior author Mien-Chie Hung, Ph.D., professor and chair of MD Anderson’s Department of Molecular and Cellular Oncology . … Read more...

Tools for improving the characterization and visualization of changes in neuro- oncology patients. … Tools for improving the characterization and visualization of changes in neuro- oncology patients Read more...

Results from the Phase II trial combining Nexavar with capecitabine were presented in 2009 by Jose Baselga, M.D., chairman and professor of medicine at Vall d’Hebron Institute of Oncology in Barcelona and the principle investigator of the … Among these clinical trials are two ongoing randomized Phase II studies, including a trial to evaluate Nexavar plus gemcitabine or capecitabine in the second-line setting following progression on bevacizumab, and a trial to evaluate … Read more...

There’s an interesting interview with Dr. Anthony Zeitman — the president of the American Society of Radiation Oncology (ASTRO) — in the most recent issue of The ASCO Post — a news magazine distributed to members of ASCO. Read more...

“Randomized clinical trials in metastatic breast cancer document that the addition of bevacizumab to some first- or second-line chemotherapy agents modestly improves time to progression and response rates but does not improve overall survival. Read more...

The Lancet Oncology , the premier worldwide journal for original oncology research, published the results of this Phase III clinical study of hyperthermia, “Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high- risk … The published study results demonstrated that the addition of regional hyperthermia, using the BSD-2000 Hyperthermia System, to chemotherapy (EIA) resulted in a significant reduction in disease progression or death, with a median … Read more...

Ovarian Cancer Support Groups – Afatinib (BIBW 2992*) Triples Progression Free Survival in Lung Cancer Patients Boehringer Ingelheim. … Cancer Support Groups – Afatinib (BIBW 2992*) Triples Progression Free Survival in Lung Cancer Patients Read more...

Contrary to what quite a few oncologists feel, sufferers with metastatic breast cancer dwell lengthier on common if their chemotherapy is continued right after their cancer is introduced underneath handle, a whole new meta-analysis reveals. The new outcomes, offered on the 35th Congress from the European Society for professional medical Oncology (ESMO), tackle a crucial Read more...

In the dutasteride group, 38 percent of the men experienced some progression of their cancer, compared with 49 percent of the men in the placebo group. This difference translated into a reduction in relative risk for cancer progression of 38.9 percent in the dutasteride group. .. Read more...

Dr Sanjay Popat, a medical oncologist at the Marsden Foundation Trust and senior lecturer in medical oncology at Imperial College London, says that when lung cancer was seen as a single disease, one all-encompassing blunt instrument could be used …. As we have seen, even the most successful of NSCLC cancer drugs using this mechanism can only extend progression -free survival by an average of 3.3 months, meaning our man in the doctor’s office may see a full year of life, … Read more...